Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 8/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396481 | 0.85 | BCHE (0.68) | BCHEFFAR1 | |
| SCHEMBL18383719 | 0.83 | CYP4F2 (0.64) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL13477505 | 0.83 | PPARA (0.58) | CYP2D6FFAR1 | |
| SCHEMBL21473721 | 0.81 | SLC2A1 (0.60) | BCHECYP2D6FFAR1 | |
| SCHEMBL2473241 | 0.80 | CHRM2 (0.66) | BCHE | |
| SCHEMBL5215124 | 0.80 | BCHE (0.66) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL17210775 | 0.80 | CYP4F2 (0.69) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL2749630 | 0.79 | CYP4F2 (0.63) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL15890882 | 0.79 | CYP2D6 (0.66) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL29683508 | 0.79 | BCHE (0.64) | BCHECYP2D6CYP4F2CYP4A11MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | BCHE 2630/4885CYP2D6 594/4885CYP4F2 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.